Navigation Links
Anthracyclines improve survival in HER2-positive breast cancer patients
Date:12/25/2007

Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors, according to a study published online December 25 in the Journal of the National Cancer Institute.

Randomized clinical trials have demonstrated that treating early breast cancer with anthracycline-based chemotherapy improves disease-free and overall survival rates more than non-anthracycline-based regimens. However, the studies have demonstrated that anthracyclines may slightly increase the risk of heart damage and leukemia. Given these side effects, the greatest benefit of these regimens may be in women with breast tumors that overexpress HER2a gene that is often amplified in tumors that respond to anthracyclines.

Alessandra Gennari, M.D., Ph.D., of the National Cancer Research Institute in Genoa, Italy, and colleagues compiled data from eight randomized controlled trials that compared anthracyclines and non-anthracyclines, and also reported HER2 status. Almost 30 percent of the patients tumors overexpressed HER2.

Overall and among patients with HER2-positive tumors, anthracycline-based chemotherapy produced a greater reduction in the risk of relapse or death than non-anthracycline-based regimens. However, among patients with HER2-negative tumors, there was no difference in survival between the chemotherapy regimens.

The absenceof any effect of anthracyclines observed in patients with HER2-negative disease suggests that this group of patients could be spared unnecessary toxic effects related to the use of this class of agents and raises questions as to the appropriateness of control arms in randomized clinical trials in which anthracycline-based regimens are used in unselected patient populations, the authors write.

In an accompanying editorial, Soonmyung Paik, M.D., of the National Surgical Adjuvant Breast and Bowel Project in Pittsburgh and colleagues point out that HER2 status alone may not be enough to determine who should receive anthracyclines, given the molecular differences among different subtypes of breast cancer.

Optimization of adjuvant chemotherapy for patients diagnosed with breast cancer will depend on defining the baseline prognosis and chemosensitivity of each subclass of breast cancer beyond those crudely defined by HER2 status alone, the editorialists write.


'/>"/>

Contact: Andrea Widener
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Vision restoration therapy shown to improve brain activity in brain injured patients
2. Broad-based group of physicians calls for improvement in stroke treatment
3. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
4. Pill box organizers increase HIV patients adherence and improve viral suppression
5. Treating depression may improve recovery of heart rate variability following coronary syndromes
6. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
7. AWWA, National Association of Water and Sanitation of Mexico, Agree to Share Expertise and Resources for Improved Water Supply
8. Exercise and yoga improves quality of life in women with early-stage breast cancer
9. QI projects may -- or may not -- improve patient safety and outcomes
10. National Association for Sport and Physical Education Partners with S&S Worldwide to Help Improve Childrens Fitness
11. MedQuist Re-launches New, Improved Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... 21, 2017 , ... Phytocéane invites you to take an exotic ... the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, a Tanzanian ... and moisturizing vegetal coral to create this gentle, crystal-clear shower gel to cleanse the ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... Austin, Texas Periodontist Dr. Dan Holtzclaw in media for its creos™ line of ... surgeries performed by Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone graft ...
(Date:1/20/2017)... ... , ... Doctor C LLC, a company based out of Arizona that focuses ... the marketing and distribution of its product, The Right C. , The Right C ... than traditional vitamin C supplements. At the trade show, Doctor C had the opportunity ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser ... Cancer Institute. For Betsy, the clinical trial has been life-saving as she has ... worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who ... the creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the ... and at 19 years of age, he joined the Navy and got married right out ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... India , January 20, 2017 According ... Type (Descriptive, Prescriptive), Application (Marketing, R&D, Compliance, SCM), Component (Software, Service), ... - Forecasts to 2021" published by MarketsandMarkets, the market is expected ... in 2016, at a CAGR of 13.3% during the forecast period. ... ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... Of Administration, End User - Forecast to 2025" report to ... The ... CAGR of around 7.8% over the next decade to reach approximately ... the global markets for Advanced Drug Delivery across all the given ...
(Date:1/20/2017)... 2017 Research and Markets has announced ... Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company ... ... Hearing Aids Market Sales Volume, Company Analysis and Forecast to ... aid industry. The growing prevalence of hearing impairment ...
Breaking Medicine Technology: